Viedoc part of large, global Covid-19 vaccine study in China

Zhongyianke Biotechnology collaborates with Viedoc in a global, phase III Covid-19 study.

Viedoc Technologies is extremely proud to be associated with an international multi-center, randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the protective efficacy, safety and immunogenicity of recombinant novel coronavirus vaccines in adults 18 years of age and older. The recombinant protein vaccine is being jointly developed by the Military Medical Research Institute of the Chinese Academy of Military Sciences, Zhongyianke Biotechnology Co., Ltd. and Liaoning Maokangyuan Biotechnology Co., Ltd., to prevent COVID 19 infections.

Recombinant protein expresses and purifies pathogen antigen proteins in engineered cells through genetic engineering, and then prepares them into vaccine. Different from the adenovirus vector vaccines and inactivated vaccines that were previously approved for clinical trials, this is a new coronavirus vaccine developed by a new technical route.

"We are proud to be working with Zhongyianke Biotechnology Co., Ltd.  on critically important trials such as this with more than 15000 subjects globally." said Viedoc Technologies CEO, Mats Klaar. “Trials like these are the very reason we have offered reduced rates in COVID-19 research. The faster we can help complete their vital Phase III, the better it will be for the health of the world."

Zhongyianke Biotechnology Co., Ltd. is pleased to collaborate with Viedoc. "Viedoc's unified eClinical solution is a critical component in the success of our efforts to develop a safe and effective vaccine against COVID-19." says Xin Wang, Project Manager, Zhongyianke Biotechnology Co., Ltd. “We were impressed by the speed and flexibility of Viedoc. For a global study like this, the demands on security and reliability were very high and ISO 27001 certified Viedoc exceeded our expectations.”

Find out how Viedoc can accelerate your trial. Contact us today.
 

Zhongyianke Biotechnology Co., Ltd. is a high-tech biotechnology company, established in 2001 and focusses on research, development, production and sales of vaccines and their intermediates. Adhering to the policy of high-level vaccine research and development, the company is committed to providing safe, high-quality and stable vaccine products for the world, making contribution to human health.

Cookies

This site uses cookies to offer you a better browsing experience. Find out more on how we use cookies and and what your options are.

Cookies

This site uses cookies to offer you a better browsing experience. Find out more on how we use cookies and and what your options are.

Your cookie preferences have been saved.